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Survival for children with acute leukaemia has improved dramati-
cally; 3-year survival among children diagnosed in Britain during
1989—91 exceeded 80% for acute lymphoblastic leukaemia (ALL)
and 50% for acute myeloid leukaemia (AML) (Stiller, 1994a). It is
widely recognized that survival rates among adults are substan-
tially lower (Proctor, 1994; Chessells et al, 1998). Recent popula-
tion-based studies of adults relate to fairly small numbers of cases,
however (Gorst and Johnson, 1992; Evensen et al, 1994; Proctor et
al, 1995; Youngson et al, 1995), and none quoted results specifi-
cally for the age group immediately following childhood.
There is a continuing debate on the optimum pattern of organi-
zation of cancer services (Expert Advisory Group, 1995; Haward,
1995; Kerr et al, 1996; Taylor, 1996) and the possible effects of
different patterns on survival (Stiller, 1994b; Selby et al, 1996).
Recently, interest has focused on the particular needs of adoles-
cents with cancer, and the first units specifically for the care of
patients in this age group have recently been set up (Souhami et al,
1996). It therefore seems particularly appropriate to carry out a
large population-based study of patterns of care and survival for
adolescents and young adults with acute leukaemia.
PATIENTS AND METHODS
Patients diagnosed with acute leukaemia at age 15—29 during
1984—94 were ascertained from the Leukaemia Research Fund
Data Collection Study (DCS) (Cartwright et al, 1997), the
leukaemia registers in the former Northern (Proctor et al, 1995),
North-Western (Gorst and Johnson, 1992), Mersey and Oxford
Regions of England and the Welsh Leukaemia Registry. There
were 879 patients in the series, 417 with ALL and 462 with AML.
As there are estimated to be 154 cases of acute leukaemia diag-
nosed at age 15—29 in England and Wales per year (Cartwright et
al, 1997), we believe that this study includes half of all cases diag-
nosed during 1984—94. Table 1 shows the coverage by region and
calendar period. Most of England and Wales was covered except
for the south-east, East Anglia and West Midlands. There was
some inter-regional variation in incidence, but the overall rates
were similar to those found for the DCS, which has been found to
be 98% complete for the 15—29 year age group (Cartwright et al,
1997), suggesting that the series is virtually complete for the
population covered.
The hospital principally responsible for the care of each patient
was determined from registry data. Hospitals were classified in
two ways:
(1) by their mean annual number of new patients aged 15—29
with acute leukaemia during the study period;
(2) as teaching or non-teaching hospitals.
During the study period, three Medical Research Council
(MRC) trials of treatment for ALL in patients aged 15 and over
were open — UKALL IX (Durrant and Richards, 1993), UKALL
XA (Durrant et al, 1997) and UKALL XII (Goldstone et al, 1997)
— and two for AML — AML9 (Rees et al, 1996) and AML10 (Hann
et al, 1997). The Clinical Trial Service Unit (CTSU) provided
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information on patients aged 15—29 who were included in these
trials.
Identifying information on all patients was sent to the National
Health Service Central Register (NHSCR) for tracing and flag-
ging. The NHSCR sent copies of death certificates for traced
patients who had died and also notified us of those who had
emigrated with resulting loss to follow-up. The remaining
flagged patients were assumed to be alive on 30 November 1997.
Death certificates or follow-up information were available by
these means for all but 18 (2.0%) of the study series. Follow-up
information was also available from the regional leukaemia
registers and CTSU, including for some patients who could not
be traced at NHSCR. Only eight (0.9%) had no follow-up from
any source.
Survival rates were calculated by standard actuarial methods.
Differences between survival curves were tested by log-rank tests
and the c2 test for linear trend. Information on remission and
relapse was not generally available. In addition to analysing
survival from the date of diagnosis, therefore, we did two further
sets of analyses:
(1) survival starting at 4 weeks after diagnosis for both ALL and
AML, in order to exclude patients who had died early, before
treatment could take effect;
(2) survival starting at 2 years after diagnosis for ALL and 1
year after diagnosis for AML, in order to study the subse-
quent survival of patients who survived long enough to
receive a full course of treatment.
RESULTS
Treatment hospitals
Table 2 shows the numbers of cases of ALL and AML treated at
different categories of hospital. Twenty-nine per cent of patients
were from hospitals seeing on average less than one new case per
year of acute leukaemia in this age group. Over half were treated at
teaching hospitals. Twenty-five younger patients (2.8% of the
whole series, 6.8% of those aged 15—19) were treated in paediatric
units. The distributions by hospital category were very similar for
ALL and AML.
MRC trials
Overall, 38% of patients were entered in MRC trials (Table 3), and
the proportions were very similar for ALL and AML. Among
patients with ALL, the entry rate was higher for those aged 15—19
at diagnosis (92/222, 41%) than for those aged 20—29 (62/195,
32%), though the difference was not quite statistically significant
(c2 = 3.74 on 1 d.f., P = 0.053); for AML, entry did not vary
substantially with age. For ALL, patients at teaching hospitals
were more likely to be entered in MRC trials (c2 = 24.8 on 1 d.f., P
< 0.0005), as were those at hospitals treating at least one study
patient per year (c2 = 12.8 on 1 d.f., P < 0.0005). For AML, the
entry rate varied between categories of hospital much less than for
ALL and any differences were non-significant. In the four regions
contributing data for the entire study period, the entry rates to ALL
trials were similar during 1984—88 and 1989—94, 34% and 31%
respectively. For AML, however, entry rose from 20% to 36%
between the two periods. Patients in the North-East ALL III trial
(Proctor et al, 1985) and other regional or single-institution studies
were counted as non-trial throughout.
Table 1 Regions of residence, years of diagnosis and diagnostic group for all patients in the
study
Number of patients
(annual incidence per million)
Region Years ALL AML Total
Northern 1984–94 60 (7.9) 51 (6.8) 112 (14.7)
Yorkshire 1984–94 53 (5.8) 59 (6.5) 112 (12.3)
Trent 1984–89 41 (6.2) 63 (9.6) 104 (15.8)
Wessex 1985–94 (Dorset) 33 (6.6) 30 (6.0) 63 (12.6)
1988–94 (remainder)
Oxford 1988–94 31 (8.5) 43 (11.8) 74 (20.4)
South West 1984–94 66 (8.4) 66 (8.4) 133 (16.8)
Mersey 1987–94 23 (5.4) 32 (7.5) 55 (12.9)
North West 1984–94 68 (6.8) 76 (7.6) 144 (14.5)
Wales 1984–940 42 (7.5) 42 (7.5) 84 (14.9)
Total 417 (7.0) 462 (7.8) 879 (14.8)
aGwent, Glamorgan and Dyfed, 1984–89 and 1991–94; Clwyd, 1987–94; Gwynedd and Powys,
1991–94.
Table 2 Main treatment hospital for patients in the study
ALL AML Total
New cases per year
in age group
<1 127 (30%) 124 (27%) 251 (29%)
1 82 (20%) 89 (19%) 171 (19%)
2–3 79 (19%) 112 (24%) 191 (22%)
4–5 122 (29%) 132 (29%) 254 (29%)
Hospitals outside
study region 5 (1%) 3 (1%) 8 (1%)
Teaching 235 (56%) 276 (60%) 511 (58%)
Other 180 (43%) 184 (40%) 364 (41%)
Unknown 2 2 4
Total 417 462 879660 CA Stiller et al
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ALL survival
The actuarial survival rates for all patients with ALL were 77% at
1 year, 60% at 2 years, 51% at 3 years, 43% at 5 years and 37% at
10 years. The results by sex, age, year of diagnosis, entry to MRC
trials and place of treatment are summarized in Table 4. While
males had a lower survival rate than females, the difference was
not significant. There was a significant trend of worsening survival
with increasing age at diagnosis. For patients aged 15—19, there
was a particularly marked improvement between 1984—88 (5-year
survival 42%) and 1989—94 (58%) (P = 0.017), whereas for those
aged 20—24 and 25—29 the increases in survival (from 34% to 42%
and from 33% to 36% respectively at 5 years) were much more
modest and not statistically significant (Figure 1). Survival was
very similar for MRC trials and non-MRC patients. There was no
evidence of any difference in survival between teaching and non-
teaching hospitals, or between hospitals treating different numbers
of study patients per year. This finding applied equally to MRC
and non-MRC patients. Mortality during the first 4 weeks after
diagnosis was 5% (20/411); of these 20 early deaths, eight (40%)
occurred during the first week. The main causes of death were
sepsis, tumour lysis and bleeding. Early mortality did not vary
significantly with sex, age, calendar period, entry in the MRC
trials or hospital category. When deaths in the first 4 weeks were
excluded, the trend of worse survival with increasing age was still
significant and the improvement between 1984—88 and 1989—94
for patients aged 15—19 was more evident (P = 0.007).
Among patients known to have survived 2 years after diagnosis,
the difference in subsequent survival between the sexes was slight,
73% of males surviving a further 3 years compared with 71% of
females. The trend with age was also non-significant, though
patients aged 15—19 had a somewhat higher chance of surviving a
further 3 years (76%) than those aged 20—29 (67%). The improve-
ment between 1984—88 and 1989—94 for patients aged 15—19 was
Table 3 Entry to MRC leukaemia trials for patients in the study
ALL AML Total
New cases per year
at hospital
<1 31/127 (24%) 43/124 (35%) 74/251 (29%)
1–5 123/283 (43%) 137/333 (41%) 260/616 (42%)
Teaching hospitals 112/235 (48%) 115/276 (42%) 227/513 (44%)
Other hospitals 42/180 (23%) 65/184 (35%) 107/364 (29%)
Total 154/417 (37%) 180/462 (39%) 334/879 (38%)
Table 4 Results of survival analyses for ALL
Factor Five-year All patients After 4 weeks After 2 years
survival (%)
(s.e.)
OEPOE P OE P
Sex
Male 41 (3.0) 172 159.6 0.10 160 146.4 0.057 53 52.6 0.94
Female 48 (4.3) 76 88.4 68 81.6 31 31.4
Age (years)
15–19 49 (3.4) 122 141.4 111 130.7 44 50.1
20–24 38 (4.6) 76 66.8 0.014 73 61.2 0.017 27 21.9 0.29
25–29 34 (5.5) 51 40.8 45 37.1 13 12.0
Year
1984–88 39 (3.4) 139 125.1 0.076 130 115.1 0.048 54 43.2 0.016
1989–94 49 (3.5) 110 123.9 99 113.9 30 40.8
MRC trial
Yes 44 (4.1) 92 95.7 0.63 84 88.2 0.57 35 32.4 0.56
No 43 (3.1) 157 153.3 145 140.8 49 51.6
Hospital type
Teaching 44 (3.3) 138 140.4 0.75 128 129.1 0.88 45 46.7 0.71
Other 43 (3.7) 109 106.6 99 97.9 38 36.3
Study patients per
year at hospital
<1 41 (4.4) 78 70.0 70 63.9 20 23.8
1 49 (5.6) 44 54.6 0.61 42 50.5 0.88 19 19.4 0.30
2–3 43 (5.7) 50 47.5 45 43.6 17 16.0
4–5 42 (4.5) 73 73.0 68 67.0 27 23.8
O, observed number of deaths; E, expected number of deaths; P, two-sided P-value from log-rank test (sex, year, MRC trial and hospital
type) or test for trend (age and study patients per year).Survival from acute leukaemia in young adults 661
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still highly significant, 69% and 85% respectively surviving a
further 3 years (P = 0.0094). Relapsed leukaemia accounted for
68/84 (81%) of deaths after 2 years, with 5/84 (6%) dying from
complications of bone marrow transplantation. Deaths from
relapsed leukaemia occurred throughout the follow-up period, the
longest survivor dying 9 years after diagnosis.
AML survival
Patients with AML had actuarial survival rates of 62% at 1 year,
48% at 2 years, 46% at 3 years, 42% at 5 years and 39% at 10
years. Thus, although the risk of death during the year following
diagnosis was appreciably greater than for ALL, long-term
survival for AML was slightly better. Other results are summa-
rized in Table 5. As with ALL, survival was lower for males than
for females, but the difference was non-significant. In contrast to
ALL, however, there was little evidence of any variation with age
at diagnosis. Survival improved significantly between 1984—88
and 1989—94 (Figure 2). During 1984—88, when the AML9 trial
was open, there was hardly any difference in survival between
MRC and non-MRC patients (35% and 37% at 5 years). During
1989—94, however, when patients were being entered in AML10,
survival was significantly higher for trial patients than for those
not entered (55% and 39% at 5 years, P = 0.012). Thus survival in
AML10 was substantially higher than in the AML9 trial, but there
was little change between the two calendar periods for patients not
in these trials. As with ALL, there was no evidence of variation in
survival between hospital categories overall, or within the MRC
and non-MRC groups.
Mortality in the first 4 weeks was 9% (43/460); 31 of these 43
deaths were in the first week. Early mortality did not vary signifi-
cantly with sex, age or calendar period. Deaths within the first
month occurred in 16/80 (20%) of patients in the M3 trial but only
27/380 (7%) of those with other subtypes of AML (c2 = 11.5 on 
1 d.f., P = 0.0006). Eleven (79%) of the 14 M3 patients who died
within 7 days had intracranial haemorrhage secondary to dissemi-
nated intravascular coagulation, compared with 4/17 (24%) for
other subtypes. There was only one death of an M3 patient from
intracranial haemorrhage after the first week. The other main
cause of early death was sepsis. Most patients were diagnosed
before October 1992, when all-trans-retinoic acid became avail-
able for treatment of M3 AML (Warrell et al, 1991). We found no
significant decrease in early deaths from intracranial haemorrhage
in M3 after that date, but the numbers were very small. Early
mortality was lower at teaching than at non-teaching hospitals
(5.4% vs 15%, c2 = 10.3 on 1 d.f., P = 0.0006) and lower at hospi-
tals treating larger numbers of study patients, ranging from 3.8%
at those with 4—5 per year to 14% at those with under one per year
(c2 = 7.53 on 1 d.f. for trend, P = 0.0061). Patients entered in MRC
trials were also less likely to die in the first 4 weeks (4.4%)
than those who were not (12%; c2 = 7.34 on 1 d.f., P = 0.0067).
Variations by sex and age in survival after 4 weeks remained non-
significant, but the improvement between 1984—88 and 1989—94
was still significant, as was the difference in survival between
MRC and non-MRC patients in 1989—94.
Among patients surviving at least 1 year, the subsequent
survival rate did not vary significantly with sex or age at diag-
nosis. The improvement between 1984—88 and 1989—94 was also
much diminished and non-significant, the chance of surviving a
further 4 years increasing only from 65% to 69%. Survival after 1
year was significantly worse for MRC trial patients (56%
surviving 4 more years) than for non-MRC patients (69%) diag-
nosed during 1984—88 (P = 0.029), whereas for 1989—94 it was
significantly better (77% MRC, 61% non-MRC; P = 0.029).
Relapsed leukaemia was the main cause of death beyond 1 year
from diagnosis (72/104, 69%), with complications of bone
marrow transplant accounting for 6/104 (6%) of deaths. The latest
death from relapsed leukaemia was at 7 years 7 months.
DISCUSSION
Over the past 25 years much attention has been given to the un-
deniably spectacular improvements in the survival of children
with ALL and, latterly, AML. This study shows that progress in
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the treatment of these diseases in adolescents and young adults has
also led to substantial improvements in survival at the population
level. Table 6 compares the changes in survival rates at age 15—29
with those found at age 0—14 over the same period in the National
Registry of Childhood Tumours. For ALL, these results confirm
on a population basis not only what has been found in the MRC
trials, namely that age is an important indicator of prognosis
beyond childhood (Chessells et al, 1998), but also that trends in
survival among patients aged 20 and over have been disap-
pointing. In the only other population-based study of trends in
survival from leukaemia in adults (defined as people aged 15 and
over, and presumably consisting predominantly of those aged over
30) no significant improvement was found between 1971—75 and
1986—90 (Badrinath et al, 1997). As the therapeutic approach in
young adults has often been similar to that in children, this
suggests that ALL in older patients differs biologically from ALL
Table 5 Results of survival analyses for AML
Factor Five-year All patients After 4 weeks After 1 year
survival (%)
(s.e.)
OEPOE P OE P
Sex
Male 38 (3.1) 161 148.9 0.14 138 125.0 0.089 61 54.2 0.20
Female 46 (3.5) 116 128.1 96 109.0 43 49.8
Age (years)
15–19 42 (4.1) 90 90.1 80 76.3 40 33.7
20–24 41 (3.9) 97 95.7 0.93 78 80.8 0.71 33 36.4 0.26
25–29 43 (4.0) 90 91.2 76 76.9 31 33.9
Year
1984–88 36 (3.4) 135 116.0 0.020 113 97.5 0.038 48 43.9 0.40
1989–94 46 (3.1) 142 161.0 121 136.5 56 60.1
MRC trial
Yes 48 (3.7) 99 115.5 0.043 91 98.1 0.34 42 43.8 0.73
No 38 (2.9) 178 161.5 143 135.9 62 60.2
Hospital type
Teaching 43 (3.0) 164 171.4 0.35 149 145.8 0.67 67 64.0 0.55
Other 40 (3.6) 112 104.6 85 88.2 37 40.0
Study patients per
year at hospital
<1 42 (4.5) 73 70.1 56 59.5 20 27.4
1 46 (5.3) 49 55.3 0.61 40 47.2 0.55 19 21.9 0.047
2–3 35 (4.5) 75 61.0 65 50.9 25 21.0
4–5 45 (4.3) 77 87.6 72 75.4 40 33.7
O, observed number of deaths; E, expected number of deaths; P, two-sided P-value from log-rank test (sex, year, MRC trial and hospital
type) or test for trend (age and study patients per year).
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in childhood (Proctor, 1994). Survival of patients aged 16—21 who
were treated on Children￿s Cancer Group protocols at paediatric
oncology centres in North America was very similar to that for
patients aged 10—15 (Nachman et al, 1993). In the UKALL XA
trial, high hyperdiploidy, which is associated with a good prog-
nosis, was more frequent among patients diagnosed aged 15—19
than among those aged 20—29, whereas the Philadelphia chromo-
some, which confers a poor prognosis, was less frequent (Secker-
Walker et al, 1997). Taken together, these results indicate that
further trials of treatment for childhood ALL might reasonably be
applicable to most patients aged up to about 20 years, while a
different approach is probably needed for the more resistant type
of disease, which is increasingly common above that age. For
AML, by contrast, there was little sign of systematic variation in
prognosis with age and the survival rates were similar to those for
children, suggesting that treatment approaches should be the same.
Population studies of patterns of care and survival should be
interpreted cautiously because of the many possible confounding
factors. Differences in prognostic factors between patients who are
entered in trials and those who are not may well change over time.
For example, a new trial using more aggressive treatment may
recruit fewer low-risk patients while simultaneously excluding
larger numbers of very ill patients because they are considered
unfit for such treatment. Referral patterns may also vary according
to perceived prognosis at presentation. Significant differences
between groups of patients may of course arise by chance or result
from incomplete control of confounding factors. Conversely, and
especially when numbers are relatively small, real effects may be
undetected. Nevertheless, such studies can provide valuable indi-
cations of the relative importance of standardized or centralized
treatment for different cancers (Stiller, 1994b; Selby et al, 1996).
The only previous investigation of the effects of patterns of care
on survival from leukaemia in adults covered lymphoid malig-
nancy diagnosed at any age from 15 years upwards in the North-
West Region of England during 1983—86 (Youngson et al, 1995).
There was thus a slight overlap between that series and ours for
ALL. Treatment according to a recognized protocol and treatment
at the regional specialist oncology centre were each associated
with significantly higher survival rates, largely because of the very
poor survival of non-protocol patients outside the regional centre.
The range of recognized protocols was not specified, however, and
features of the single oncology centre other than its specialization
may have been responsible for the higher survival rate observed
there.
Children with ALL diagnosed in Britain during 1971—84 had a
higher survival rate if they entered in the MRC trials or were
treated at hospitals seeing larger numbers of children with this
disease (Stiller and Draper, 1989). Among MRC trial patients,
place of treatment made little difference to survival, and the only
group identified as having a notably worse prognosis consisted of
children who were not entered in the trials and were treated at a
hospital with few patients. For childhood AML diagnosed during
1975—83, survival was worse among non-trial patients, but during
1984—88 [when children tended to be entered in the ￿Joint AML￿
study (Marcus et al, 1987) rather than MRC trials] the difference
had disappeared (Stiller and Eatock, 1994), as in the present study
of young adults. In the earlier period children treated at teaching
hospitals had a higher survival rate, but by 1984—88 too few 
children were treated at non-teaching hospitals for a meaningful
comparison.
In the present study, patients with ALL had a similar survival
rate whether or not they were entered in MRC trials. The high
early mortality among non-MRC patients with AML presumably
reflects a tendency not to enter severely ill patients in the trials, in
some cases because they had died before they could be entered.
Survival in AML10, which was open from 1988 to 1995, was
better than in any previous randomized trial of treatment for AML
(Hann et al, 1997). We have no information on the treatment given
to individual patients, but the emergence since 1989 of a longer
term survival advantage for patients who were entered in AML10
over those who were not is consistent with some more recently
diagnosed non-trial patients receiving less effective treatment
similar to that used during the previous 5 years.
In general, we found no survival advantage associated with 
treatment at hospitals with larger numbers of young adult acute
leukaemia patients or at teaching hospitals. It is impossible to be
certain why there should have been higher early mortality among
AML patients at non-teaching hospitals or smaller centres. Severely
ill patients could well be less likely to be referred to a tertiary centre,
but differences in supportive care cannot be ruled out.
It is perhaps not surprising that we should have found less
evidence of survival variations by place of treatment than in earlier
studies of childhood leukaemia. The childhood studies would have
included virtually all children treated by paediatric specialists,
whereas patients aged 15—29 represent 42% of persons aged 15—64
with ALL and only 15% of those with AML (Cartwright et al,
1997). Thus, even hospitals with only one new patient per year
with acute leukaemia aged 15—29 could well have seen 4—5
patients per year aged 15—64. Most patients were treated according
to a standard MRC or other protocol (Benjamin et al, 1997),
consistent with the absence of any variation in survival with
hospital category even among non-MRC patients. Many were not
actually entered in MRC trials, inevitably lessening the ability of
these trials to answer rapidly the questions that they were set up to
investigate.
The entry rate to the trials was lower at non-teaching hospitals
and those with smaller numbers of leukaemia patients, especially
for ALL. A very large number of hospitals participated in AML10,
with an average entry rate of fewer than two patients per centre per
year (Hann et al, 1997), but this did not prevent the attainment of
exceptionally high survival rates. We also found no difference in
survival by place of treatment for trial patients. Thus, while greater
centralization of treatment might result in higher recruitment to
trials, this could also be achieved by improving the entry rate from
smaller centres without compromising survival. The reasons for
lower participation rates from smaller centres require further
study.
Table 6 Population-based 5-year survival rate (%) for acute leukaemia in
Britain
Age at diagnosis (completed years)
0 1–4 5–9 10–14 15–19 20–24 25–29
ALL
1984–88 26 81 72 55 42 34 33
1989–94 35 86 79 73 58 42 36
AML
1984–88 23 35 40 37 40 37 30
1989–94 45 56 53 49 44 43 50
Sources: National Registry of Childhood Tumours (age 0–14); present study
(age 15–29).664 CA Stiller et al
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One possible reason for the poor survival in an earlier period of
children who received their treatment for ALL at a centre with few
such patients and outside the MRC trials may be that these were
the children who did not benefit from the collective experience
within a specialist centre or a cooperative trials group. For adults
with acute leukaemia, apart from the fact that most of them are
treated according to accepted protocols, the growth of collabora-
tive regional haematology groups provides the necessary pooling
of experience to bring about uniformity of care (Charlton et al,
1997). Collaboration also facilitates the collection of high-quality,
unbiased data, making possible studies such as the one reported
here. This pattern is spreading to more areas of the country; regis-
ters of leukaemia patients in the West Midlands and former South-
East Thames regions have been established, though too recently
for inclusion in this study.
Treatment of adolescents in specialist oncology units dedicated
to this age group has been advocated on two main grounds,
medical and social, the medical case being founded on higher
survival rates. In a survey of haematology departments in our
study regions, we found hardly any units reserved for adolescents
or young adults and therefore could not address directly the ques-
tion of survival rates in adolescent units (Benjamin et al, 1997).
However, our results provide no evidence of a survival advantage
associated with the centralized treatment of acute leukaemias in
this age group. The social case is that young people would prefer
to be treated in a different environment from other, predominantly
elderly cancer patients. Alternatively, adolescents and young
adults may prefer to be treated near to where their friends live, and
the necessity of travelling long distances and being resident for
long periods in tertiary referral centres could result in depression
and non-compliance with treatment. The present study could not
provide any evidence on this point. However, while moves are
afoot to provide more dedicated units for the treatment of patients
with solid tumours in the age group discussed here it must remain
in doubt whether such developments would have any impact on
survival from leukaemia.
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